Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026
Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Feb 14, 2026
Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Fineline Cube Feb 13, 2026
Company Deals

IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China

Fineline Cube Apr 9, 2025

Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...

Company

Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales

Fineline Cube Apr 9, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...

Company Drug

Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia

Fineline Cube Apr 9, 2025

China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...

Company Medical Device

HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation

Fineline Cube Apr 9, 2025

Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...

Company Drug

Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial

Fineline Cube Apr 9, 2025

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...

Company Drug

Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis

Fineline Cube Apr 9, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials

Fineline Cube Apr 9, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Amgen’s Uplizna Approved by FDA for IgG4-Related Disease

Fineline Cube Apr 8, 2025

US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...

Company Drug

J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment

Fineline Cube Apr 8, 2025

The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...

Company Deals

TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China

Fineline Cube Apr 8, 2025

China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...

Company Drug

J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma

Fineline Cube Apr 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...

Policy / Regulatory

Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation

Fineline Cube Apr 8, 2025

Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA

Fineline Cube Apr 8, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...

Company Drug

SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study

Fineline Cube Apr 8, 2025

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...

Company Drug

Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau

Fineline Cube Apr 8, 2025

China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...

Company Drug

Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation

Fineline Cube Apr 8, 2025

China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...

Company Drug

Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion

Fineline Cube Apr 8, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...

Company Drug

Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors

Fineline Cube Apr 8, 2025

China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...

Policy / Regulatory

Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency

Fineline Cube Apr 8, 2025

The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...

Company Deals

Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China

Fineline Cube Apr 8, 2025

In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...

Posts pagination

1 … 140 141 142 … 625

Recent updates

  • Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology
  • VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
  • Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY
  • Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31
  • 3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Medical Device

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.